Sort
48,018 grants matching “immunotherapy”
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
$458,317David G Denardo · Washington University · R01 · FY2020 · CA
Immune regulation of tissue iron in health and disease
$458,314Nicholas J. Bessman · Rutgers Biomedical And Health Sciences · DP2 · FY2023 · AI
NK Memory
$458,300Lewis L. Lanier · University Of California, San Francisco · R01 · FY2020 · AI
Regulation by Gammadelta T Cells of Autoimmune Uveitis (EAU)
$458,279Deming Sun · Doheny Eye Institute · R01 · FY2013 · EY
Biomaterials for Targeted Modulation of Conventional Type 1 Dendritic Cells
$458,277Hua Wang · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
$458,203Zelig Eshhar · Tel-Aviv Sourasky Medical Center · R01 · FY2013 · EB
Imaging Costimulation Blockade Resistant Rejection
$458,199Andrew B Adams · Emory University · U01 · FY2019 · AI
An innate immune checkpoint in cancer immunotherapy
$458,186Carla Rothlin · Yale University · R01 · FY2021 · CA
Deciphering the specificity and molecular mechanisms of regulatory T cells using novel approaches
$458,125Billur Akkaya · Ohio State University · DP2 · FY2022 · AI
Cancer and Leukemia Group B
$458,112Dana-Farber Cancer Institute · U10 · FY2003 · CA
Clinical Trials in Mesothelioma
$458,054Daniel Sterman · University Of Pennsylvania · P01 · FY2007 · CA
Calreticulin-mediated protein folding in health and disease
$458,052Malini Raghavan · University Of Michigan At Ann Arbor · R01 · FY2022 · AI
Immunotherapy of low grade lymphoid malignancies
$457,995Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2016 · HL
02 - Experimental Therapeutics
$457,959Suzanne Elizabeth Lapi · University Of Alabama At Birmingham · P30 · FY2025 · CA
Regulatory and effector T cells in oral immunotherapy for food allergy
$457,946Wayne G Shreffler · Massachusetts General Hospital · U19 · FY2012 · AI
SOLUBLE LYMPHOCYTE ACTIVATION GENE-3 (s-LAG-3) AND INSULIN m-RNA: A POTENTIAL SURROGATE MARKERS FOR DISEASE PROGRESSION AND IMMUNOTHERAPY
$457,877Jon D Piganelli · Indiana University Indianapolis · R21 · FY2025 · AI
Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
$457,861Eric Kirk Lau · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$457,796Deming Sun · Doheny Eye Institute · R01 · FY2022 · EY
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$457,796Deming Sun · Doheny Eye Institute · R01 · FY2021 · EY
Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process.
$457,791Dennis Roop · University Of Colorado Denver · R01 · FY2025 · AR
INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION
$457,787Weill Medical College Of Cornell Univ · U01 · FY2003 · AI
Targeting PP4 to improve ovarian cancer response to immunotherapy
$457,776Marion Curtis · Mayo Clinic Arizona · R37 · FY2025 · CA
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
$457,754Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer
$457,731Kevin Finnbar Staveleyo'carroll · University Of Missouri-Columbia · R01 · FY2023 · CA
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma
$457,723Muhammed Murtaza · Translational Genomics Research Inst · R01 · FY2018 · CA